E-LIB Suche - Ergebnisse für: Gilloteau, I.

1

PBI24 SECUKINUMAB VS ADALIMUMAB FOR THE TREATMENT OF ANKYLO..:

Mestouri, A. ; Kooli, A. ; Bouchaour, N..
Value in Health. 22 (2019) - p. S421 , 2019

Link: https://doi.org/10.1016/..

2

PSY19 A COST PER RESPONDER ANALYSIS OF SECUKINUMAB COMPARED..:

Yahiaoui, S. ; Panguluri, S. ; MZah, D....
Value in Health. 22 (2019) - p. S904-S905 , 2019

Link: https://doi.org/10.1016/..

3

Cost‐effectiveness of secukinumab as first biologic treatme..:

Augustin, M. ; McBride, D. ; Gilloteau, I....
Journal of the European Academy of Dermatology and Venereology. 32 (2018) 12 - p. 2191-2199 , 2018

Link: https://doi.org/10.1111/..

4

Psoriasis: clinical and epidemiological features and therap..:

Bakulev, A. L. ; Fitileva, T. V. ; Novodezerkina, E. А....
Vestnik dermatologii i venerologii. 94 (2018) 3 - p. 67-76 , 2018

Link: https://doi.org/10.25208..

5

PSS31 - COST PER RESPONDER OF SECUKINUMAB COMPARED TO OTHER..:

Suzuki, C. ; Lopes, N. ; Gilloteau, I..
Value in Health. 21 (2018) - p. S428 , 2018

Link: https://doi.org/10.1016/..

6

PSS41 - SECUKINUMAB SIGNIFICANTLY REDUCES PSORIASIS-RELATED..:

Kooli, A. ; Graham, C. ; Scheuer, N....
Value in Health. 21 (2018) - p. S429 , 2018

Link: https://doi.org/10.1016/..

7

PSS33 - SECUKINUMAB AS FIRST BIOLOGIC TREATMENT: A COST PER..:

Bianculli, P.M. ; Salibe, M. ; Peirano, I...
Value in Health. 21 (2018) - p. S428 , 2018

Link: https://doi.org/10.1016/..

8

PSS42 - SECUKINUMAB SIGNIFICANTLY REDUCES PSORIASIS-RELATED..:

Kooli, A. ; Graham, C. ; Scheuer, N....
Value in Health. 21 (2018) - p. S430 , 2018

Link: https://doi.org/10.1016/..

9

Patient Reported Outcomes in Psoriasis Treatment Decision M..:

Feldman, SR ; Regnier, SA ; Gilloteau, I...
Value in Health. 21 (2018) - p. S242 , 2018

Link: https://doi.org/10.1016/..

10

A multidimensional overview of the burden of psoriasis:

Griffiths, C.E.M. ; Jo, S.-J. ; Naldi, L....
British Journal of Dermatology. 179 (2018) 1 - p. e67-e67 , 2018

Link: https://doi.org/10.1111/..

11

PSS68 - THE MOST INFLUENTIAL DRIVERS OF PSORIASIS PATIENTS'..:

Poulos, C. ; Feldman, S.R. ; Gilloteau, I....
Value in Health. 21 (2018) - p. S434-S435 , 2018

Link: https://doi.org/10.1016/..

12

Cost Per Responder of Secukinumab Compared to Other Biologi..:

Suzuki, C ; Lopes, N ; Tozato, C..
Value in Health. 21 (2018) - p. S240 , 2018

Link: https://doi.org/10.1016/..

13

A multidimensional assessment of the burden of psoriasis: r..:

Griffiths, C.E.M. ; Jo, S.-J. ; Naldi, L....
British Journal of Dermatology. 179 (2018) 1 - p. 173-181 , 2018

Link: https://doi.org/10.1111/..

14

Cost Per-Responder Analysis of Secukinumab Compared to Othe..:

Al Howimel, M ; Al Jufan, K ; AlAlwan, A...
Value in Health. 21 (2018) - p. S106 , 2018

Link: https://doi.org/10.1016/..

15

Secukinumab significantly reduces psoriasis‐related work im..:

Warren, R.B. ; Halliday, A. ; Graham, C.N....
Journal of the European Academy of Dermatology and Venereology. 32 (2018) 12 - p. 2178-2184 , 2018

Link: https://doi.org/10.1111/..